Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. Design studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results

COVID-19 prophylaxis (excluding childrens) meta-analysis

C4591031- first boost, 2021
 
NCT04955626
RCTComirnaty - first boostComirnaty (tozinameran - Pfizer/BIONTECH)COVID-19 prophylaxis (excluding childrens)low
5081/5044 conclusif
  • demonstrated 95 % decrease in confirmed COVID (any severity) (PE) with a high degree of certainty due to low risk of bias
C4591031- first boost, 2021
 
NCT04955626
RCTComirnaty - first boostcomplete primary vaccine seriesCOVID-19 prophylaxis (excluding childrens)low
5081/5044 conclusif
  • demonstrated 95 % decrease in confirmed COVID (any severity) (PE) with a high degree of certainty due to low risk of bias

PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).